CENTRAL TRUST Co Sells 8,399 Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP)

CENTRAL TRUST Co decreased its position in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) by 24.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,280 shares of the biopharmaceutical company’s stock after selling 8,399 shares during the period. CENTRAL TRUST Co’s holdings in Horizon Therapeutics Public were worth $1,564,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. Barclays PLC lifted its position in shares of Horizon Therapeutics Public by 1,235.5% during the third quarter. Barclays PLC now owns 3,852,296 shares of the biopharmaceutical company’s stock valued at $238,420,000 after buying an additional 3,563,851 shares during the last quarter. Marshall Wace LLP lifted its holdings in Horizon Therapeutics Public by 1,481.3% in the 3rd quarter. Marshall Wace LLP now owns 2,506,329 shares of the biopharmaceutical company’s stock valued at $155,118,000 after purchasing an additional 2,347,834 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Horizon Therapeutics Public in the 3rd quarter worth $129,622,000. Alliancebernstein L.P. increased its stake in shares of Horizon Therapeutics Public by 432.9% in the 3rd quarter. Alliancebernstein L.P. now owns 1,495,840 shares of the biopharmaceutical company’s stock worth $92,578,000 after acquiring an additional 1,215,164 shares during the last quarter. Finally, Neuberger Berman Group LLC increased its position in shares of Horizon Therapeutics Public by 216.2% during the 3rd quarter. Neuberger Berman Group LLC now owns 1,519,040 shares of the biopharmaceutical company’s stock worth $94,013,000 after purchasing an additional 1,038,577 shares during the last quarter. Institutional investors own 91.01% of the company’s stock.

Insiders Place Their Bets

In other Horizon Therapeutics Public news, EVP Jeffrey W. Sherman sold 5,187 shares of the stock in a transaction dated Friday, January 6th. The stock was sold at an average price of $113.29, for a total transaction of $587,635.23. Following the completion of the transaction, the executive vice president now owns 49,314 shares in the company, valued at approximately $5,586,783.06. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, EVP Jeffrey W. Sherman sold 5,187 shares of the stock in a transaction dated Friday, January 6th. The shares were sold at an average price of $113.29, for a total transaction of $587,635.23. Following the completion of the transaction, the executive vice president now directly owns 49,314 shares in the company, valued at approximately $5,586,783.06. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Andy Pasternak sold 27,129 shares of the stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $113.03, for a total transaction of $3,066,390.87. Following the transaction, the executive vice president now owns 56,338 shares of the company’s stock, valued at $6,367,884.14. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,832 shares of company stock worth $8,125,648. Corporate insiders own 2.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Guggenheim cut Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $98.00 to $116.50 in a research note on Tuesday, December 13th. SVB Leerink lowered Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating and upped their price objective for the stock from $88.00 to $116.50 in a report on Tuesday, December 13th. Wells Fargo & Company downgraded Horizon Therapeutics Public from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $118.00 to $116.50 in a research report on Monday, December 12th. BMO Capital Markets downgraded Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 13th. Finally, StockNews.com started coverage on Horizon Therapeutics Public in a research note on Friday, March 10th. They set a “buy” rating for the company. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $111.42.

Horizon Therapeutics Public Stock Down 0.2 %

NASDAQ:HZNP opened at $109.47 on Thursday. The stock’s fifty day moving average price is $110.95 and its two-hundred day moving average price is $89.82. Horizon Therapeutics Public Limited has a 52-week low of $57.84 and a 52-week high of $117.49. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.67 and a current ratio of 3.85. The company has a market cap of $25.01 billion, a price-to-earnings ratio of 49.15, a P/E/G ratio of 3.84 and a beta of 1.15.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its earnings results on Wednesday, March 1st. The biopharmaceutical company reported $1.21 EPS for the quarter, beating the consensus estimate of $1.09 by $0.12. The company had revenue of $942.03 million during the quarter, compared to analysts’ expectations of $922.95 million. Horizon Therapeutics Public had a net margin of 14.37% and a return on equity of 23.04%. The business’s revenue for the quarter was down 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.41 EPS. On average, analysts anticipate that Horizon Therapeutics Public Limited will post 5.73 EPS for the current year.

Horizon Therapeutics Public Profile

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.